Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Drug Pricing Rules to Be Applied to Oncolytic Virus Delytact: Chuikyo
Japan’s all-important reimbursement policy panel on June 23 agreed to apply drug pricing rules for Daiichi Sankyo’s Delytact (G47∆; teserpaturev), the world’s first-ever oncolytic virus approved for the treatment of malignant glioma. Delytact was granted conditional, time-limited approval on June…
To read the full story
Related Article
- J-TEC’s Ocural, Cell Sheet for Eye Disease, Launched in Japan
December 13, 2021
- Daiichi Sankyo Launches Oncolytic Virus Delytact in Japan
November 2, 2021
- J-TEC’s Oral Mucosal Cell Sheet Ocural Earns NHI Listing
September 16, 2021
- Delytact Gets 1.43 Million Yen Price Tag
August 4, 2021
- Architect of Oncolytic Virus Therapy Looks to Its Use in All Solid Cancers in 5 Years
June 25, 2021
- Japan Approves J-TEC’s Mucosal Cell Sheet for Corneal Stem Cell Deficiency
June 14, 2021
- Japan Approves 1st Oncolytic Virus, Delytact, for Malignant Glioma
June 14, 2021
- MHLW Panel Backs Japan’s 1st Oncolytic Virus for Conditional Approval
May 25, 2021
- Daiichi Sankyo Files Sakigake-Designated Oncolytic Virus in Japan After Overcoming Manufacturing Issues
January 6, 2021
- J-TEC Files Mucosal Cell Sheet for Corneal Epithelial Stem Cell Deficiency in Japan
September 15, 2020
- Submission of Oncolytic Virus G47Δ Lagging as Team Still Preps for Manufacturing
July 22, 2019
REGULATORY
- LDP, Ishin Still at Odds on Social Security Reform; Pharma Role in Chuikyo Gains Traction
June 19, 2026
- MHLW Panel OKs Technical Review Group for OTC-Like Drug Charge System
June 19, 2026
- MHLW Official Warns of High Risks from GLP-1 Use in Cosmetic Weight Loss
June 19, 2026
- LDP to Launch Study Group on Lag and Loss of Pediatric Cancer Drugs
June 19, 2026
- LDP Patch League Urges Drug Price Support as Costs Continue to Climb
June 19, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…